Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell
dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients …

Inflammation is a key driver in many pathological conditions such as allergy, cancer,
Alzheimer's disease, and many others, and the current state of available drugs prompted …

Obesity is a state of low-grade chronic inflammation that causes multiple metabolic
diseases. During obesity, signalling via cytokines of the TNF family mediate cell death and …

Obesity is becoming an epidemic in the United States and worldwide and increases risk for
many diseases, particularly insulin resistance, type 2 diabetes mellitus, and cardiovascular …

The involvement of inflammasomes in the proinflammatory response observed in chronic
liver diseases, such as alcohol-associated liver disease (ALD) and nonalcoholic fatty liver …

Obesity is one of the major health burdens of the 21st century as it contributes to the growing
prevalence of its related comorbidities, including insulin resistance and type 2 diabetes …

Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2
diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these …

NLRP3 is the best characterized cytosolic nod-like pattern recognition receptor which can
detect microbial motifs, endogenous danger and stress signals. Activation of NLRP3 leads to …